Dry (Atrophic) Macular Degeneration – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Dry (Atrophic) Macular Degeneration – Drugs In Development, 2023’, provides an overview of the Dry (Atrophic) Macular Degeneration pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration
- The report reviews pipeline therapeutics for Dry (Atrophic) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dry (Atrophic) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Dry (Atrophic) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dry (Atrophic) Macular Degeneration
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
4P-Pharma SASAdverum Biotechnologies Inc
Aevitas Therapeutics Inc
AffaMed Therapeutics US Inc
Allegro Ophthalmics LLC
Allife Medical Science and Technology Co Ltd
Astellas Pharma Inc
Aviceda Therapeutics Inc
Belite Bio Inc
Beta Therapeutics Pty Ltd
Biophytis SA
CAMP Therapeutics Inc
Caregen Co Ltd
Character Biosciences Inc
CHS Pharma Inc
CIRC Biosciences Inc
Cognition Therapeutics Inc
Complement Therapeutics Ltd
Curative Biotechnology Inc
Eluminex Biosciences Ltd
Exopharm Ltd
Eye Co Pty Ltd
Eyestem Research Pvt Ltd
Eyevensys SAS
F. Hoffmann-La Roche Ltd
FasT Biopharma Ltd
Galactica Pharmaceuticals
Inc.
Galimedix Therapeutics Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
Healios KK
Hefei Starry Gene Biotechnology Co Ltd
Ichor Life Sciences Inc
Inflammx Therapeutics Inc
Isarna Therapeutics GmbH
Johnson & Johnson
Kanaph Therapeutics Inc
Kira Pharmaceuticals
Kodiak Sciences Inc
Kuria Therapeutics Inc
Laboratoires Thea SA
Limnopharma SL
Luxa Biotechnology LLC
MD Healthcare Inc
Mitotech SA
Mperia Therapeutics Inc
Nanoscope Therapeutics Inc
NovelMed Therapeutics Inc
Ocugen Inc
Ocular Therapeutix Inc
Oculo Therapy LLC
Oculogenex Inc
OcuNexus Therapeutics Inc
OliX Pharmaceuticals Inc
ONL Therapeutics Inc
Opsis Therapeutics LLC
Oxurion NV
Perceive Biotherapeutics Inc
Proen Therapeutics Co Ltd
Protokinetix Inc
Retrotope Inc
RevOpsis Therapeutics Corp
Ripple therapeutics Corp
SanBio Co Ltd
SEASUN THERAPEUTICS Inc
Shenzhen Evergreen Therapeutics Co Ltd
Snyder Biomedical Corp
Stealth BioTherapeutics Inc.
Stuart Therapeutics Inc
Surrozen Inc
SynCore Biotechnology Co Ltd
Tarsier Pharma Ltd
Theratocular Biotek Co Ltd
Topadur Pharma AG
Translatum Medicus Inc
University of Florida
University of Pittsburgh
USA Elixiria Biotech Inc
VasThera Co Ltd
Vertex Pharmaceuticals Inc
Visgenx Inc
Vzarii Therapeutics Ltd
Xilingyuan Pharmaceutical Co Ltd
Zhejiang Doer Biologics Corp